

Supplementary Table S2: Type I and II MET kinase inhibitors and key trials studying their activity lung cancer populations enriched for MET-dependence.

MET kinase inhibitor	MET amplification or MET exon 14 mutation	Acquired resistance to EGFR TKI
Type I inhibitors		
Crizotinib	NCT00585195 NCT02664935	NCT01121575 (with dacomitinib)
Savolitinib		NCT02374645 (with gefitinib) NCT02143466 (with osimertinib)
INC280	NCT02414139 NCT02276027	NCT01610336 (with gefitinib) NCT02468661 (with erlotinib) NCT02335944 (with EGF816)
MSC2156119J		NCT01982955 (with gefitinib)
Type II inhibitors		
Cabozantinib	NCT01639508	NCT01866410 (with erlotinib)
MGCD265	NCT02544633	
Merestinib		